Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study

Fig. 1

Graph A shows that the HR and CR rates at 3 months were 46.9% vs. 37.5% and 21.9% vs. 5.2%, respectively, in the two groups. Graph B shows that the HR and CR rates at 6 months were 68.7% vs. 50.0% and 34.4% vs. 14.6%, respectively, in the two groups. Graph C shows the haematologic responses over time in each patient. In total, 23 patients had a response after hetrombopag with IST treatment. However, patients No. 15 and No. 19 had disease relapse, one owing to discontinued hetrombopag, and the reason was unknown for the other. Patients No. 16 and No. 27 had fluctuating platelet counts of < 100 × 109/L after discontinuing hetrombopag; however, their platelet counts returned to normal after re-initiation of hetrombopag at a dose of 7.5 mg. Only one patient died during HSCT at 393 days after IST. HR haematologic response, CR complete response

Back to article page